We are live on
!
Find out more
Axsome Therapeutics
AXSM
AXSM
292 hedge funds and large institutions have $3.15B invested in Axsome Therapeutics in 2024 Q4 according to their latest regulatory filings, with 61 funds opening new positions, 91 increasing their positions, 90 reducing their positions, and 40 closing their positions.
New
Increased
Maintained
Reduced
Closed
53% more first-time investments, than exits
New positions opened: 61 | Existing positions closed: 40
49% more call options, than puts
Call options by funds: $181M | Put options by funds: $121M
38% more funds holding in top 10
Funds holding in top 10: 8 → 11 (+3)
5% more funds holding
Funds holding: 279 → 292 (+13)
1% more repeat investments, than reductions
Existing positions increased: 91 | Existing positions reduced: 90
3.85% less ownership
Funds ownership: 80.58% → 76.73% (-3.8%)
9% less capital invested
Capital invested by funds: $3.47B → $3.15B (-$328M)
Holders
292
Holders Change
+13
Holders Change %
+4.66%
% of All Funds
3.85%
Holding in Top 10
11
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+37.5%
% of All Funds
0.14%
New
61
Increased
91
Reduced
90
Closed
40
Calls
$181M
Puts
$121M
Net Calls
+$59.4M
Net Calls Change
+$57.8M
Top Buyers
| 1 |
Lazard Asset Management
New York
|
+$41.5M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
+$31.5M |
| 3 |
Principal Financial Group
Des Moines,
Iowa
|
+$18.7M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$17.5M |
| 5 |
BNP Paribas Financial Markets
Paris,
France
|
+$15.8M |
